Eli Lilly and Company acquisition of Kelonia Therapeutics
US$7bn consideration
Announced 20 Apr 2026
Advisers
Kelonia Therapeutics
Target
- Financial adviser
- Legal adviser
- Goodwin

Team: Rachael Bushey, Allison P. Nicklin, Sarah Solomon, Evan Lee, Neil Doogan, Jennifer Ford, Julia Shaver, Spencer Kahn, Madeleine Popp, Nick O'Grady, Hayden Hunt, Bonnee Nie, Hugh Rennie, Dan Karelitz, Sarah Bock, James Devendorf, Dasol Lee, Jennifer Fay, Michael Faikes, Arman Oruc, Danielle Fong, Bill Christiansen, Duncan Greenhalgh, Susan Lee, Joseph Harrington, Jonathan Ishee, Michael Paluzzi
Eli Lilly and Company
Acquirer
- Legal adviser
- Kirkland & Ellis

Team: Allie Wein, Sarkis Jebejian, Brian Junquera, Steven Choi, Amir Farahani, Seung Bo Choi, Aaron Eisen, Bailey Ellis, Dean Shulman, Liam Murphy, Daniel Henry, Andrea Murino, Samantha Morelli, Shellie Freedman, Rami Sherman, Julia Monti, Robert Fowler, Sally Ye, Lilibeth Clelo-Garcha, Cassandra Zárate, Kiyong Song, Brian King, Alexa Auger
- Target
- Kelonia Therapeutics
- Acquirer
- Eli Lilly and Company
- Target based in
- United States (unverified)
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Cell Therapy, Oncology
In the league tables
Similar deals
- Gilead Sciences acquisition of Arcellx Feb 2026 · US$7.8bn · Biotech
- AstraZeneca acquisition of AbelZeta's 50% share of China development and commercialisation rights to C-CAR031 Jan 2026 · US$630m · Biotech
- Galera Therapeutics and Obsidian Therapeutics merger Apr 2026 · US$414m · Biotech
- Merck & Co. acquisition of Terns Pharmaceuticals Mar 2026 · US$6.7bn · Biotech
- GSK acquisition of Nuvalent Jun 2026 · US$11bn · Biotech
Sources
- Apr 2026 Kirkland Advises Eli Lilly on Acquisition of Kelonia Therapeutics kirkland.com
- 20 Apr 2026 Press release (PR Newswire), Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies prnewswire.com
- 21 Apr 2026 Goodwin Advises Kelonia Therapeutics in Acquisition by Lilly for $7 Billion, Largest In-Vivo CAR-T Deal to Date goodwinlaw.com
